Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Alastair Greystoke.

Newcastle AuthorsTitleYearFull text
Professor Gareth Veal
Professor Steve Wedge
Dr Christopher Bacon
Professor Philip Sloan
Professor Alastair Greystoke
et al.
A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer2023
Dr Ruth Norris
Dr Liz Fuller
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
et al.
OP41 Routes to diagnosis in lung cancer – do socio-demographics matter? An English population-based study2023
Dr Ruth Norris
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
OP42 Socio-economic inequalities in novel NSCLC treatments during the era of tumour biomarker guided therapy: a population-based cohort study2023
Sarah Rae
Dr Linda Hogarth
Alison Bridgewood
Lisa Brown-Schofield
Dr Saira Bashir
et al.
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders2023
Dr Ruth Norris
Dr Rosie Dew
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
et al.
Socio-economic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker Guided Therapy: A Population-based Cohort Study in a Publicly Funded Healthcare System2023
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al.
A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the ChemoFit study2022
Dr Matthew Cooper
Jakub Chmelo
Dr Rhona Sinclair
Dr Sarah Charman
Dr Kate Hallsworth
et al.
Exploring factors influencing uptake and adherence to a home-based prehabilitation physical activity and exercise intervention for patients undergoing chemotherapy before major surgery (ChemoFit): a qualitative study2022
Dr Ruth Norris
Professor Adam Todd
Professor Alastair Greystoke
Professor Linda Sharp
OA01.05 Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study2022
Professor Alastair Greystoke
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study2022
Jenny Welford
Kathryn Hunt
Louise Duncan
Dr Ann Ward
Professor Adam Todd
et al.
The Clinical Frailty Scale can indicate prognosis and care requirements on discharge in oncology and haemato-oncology inpatients: A cohort study.2022
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Alex Bradshaw
Dr Rhona Sinclair
et al.
Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve2021
Professor Alastair Greystoke
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer2021
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al.
A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol2020
Ruth Norris
Dr Rosie Dew
Professor Linda Sharp
Professor Alastair Greystoke
Dr Sarah Rice
et al.
Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis2020
Dr Nicola Hannaway
Professor Alastair Greystoke
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer2020
Dr Eleanor Smith
Professor Alastair Greystoke
The care of older cancer patients in the United Kingdom2020
Professor Alastair Greystoke
The National Lung Matrix Trial of personalised therapy in lung cancer2020
Professor Alastair Greystoke
105O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study2019
Professor Alastair Greystoke
140P - Brigatinib experience on the ALK project2019
Professor Ruth Plummer
Professor Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Alice Coomer
Dr Fiona Black
Professor Alastair Greystoke
Dr Jennifer Munkley
Professor David Elliott
et al.
Alternative splicing in lung cancer2019
Professor Alastair Greystoke
Implications for UK practice of the use of durvalumab in stage III NSCLC2019
Professor Alastair Greystoke
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomalformulation in patients with solid tumours2019
Dr Maziar Navidi
Professor Alexander Phillips
Professor Michael Griffin
Professor Alastair Greystoke
Dr Kate Sumpter
et al.
Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer2018
Dr Joanna Perthen
Dr Tamir Ali
David McCulloch
Maziar Navidi
Professor Alexander Phillips
et al.
Intra- and Interobserver Variability in Skeletal Muscle Measurements using Computed Tomography Images2018
Professor Alastair Greystoke
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)2017
Professor Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Patterson
Dr David Jamieson
et al.
Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)2016
Dr Sally Hall
Professor Alastair Greystoke
Dr Christopher Jones
Dr Jane Margetts
Crizotinib in clinical practice: the North East of England's experience2016
Professor Alastair Greystoke
Development of a circulating miRNA assay to monitor tumor burden: From mouse to man2016
Professor Ruth Plummer
Professor Alastair Greystoke
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting2016
Professor Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Patterson
Liam Bolt
Dianne Turner
et al.
The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained2016
Dr Yvette Drew
Professor Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Professor Ruth Plummer
Professor Alastair Greystoke
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors2015
Professor Alastair Greystoke
An Introduction to Stratified Medicine2015
Professor Alastair Greystoke
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD20142015
Professor Vinidh Paleri
Professor Alastair Greystoke
Dr Charles Kelly
Spindle cell carcinoma of the head and neck region: Treatment and outcomes of 15 patients2015
Dr Manolo D'Arcangelo
Dr Jane Margetts
Professor Alastair Greystoke
The use of circulating biomarkers in early clinical trials in patients with cancer2015
Professor Alastair Greystoke
A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors2014
Professor Alastair Greystoke
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer2014
Professor Alastair Greystoke
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity2013
Professor Alastair Greystoke
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication2013
Professor Alastair Greystoke
A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients2012
Professor Alastair Greystoke
Biomarkers of cell death applicable to early clinical trials2012
Professor Alastair Greystoke
Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer2012
Professor Alastair Greystoke
How Many Diseases Are Colorectal Cancer?2012
Professor Alastair Greystoke
Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents2012
Professor Alastair Greystoke
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer2012
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Professor Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005